About: Oncophage     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:Vaccine104517535, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/c/6E5QQvkcrS

Oncophage (brand name Vitespen), also known as cancer vaccine heat shock protein peptide complex-96 and cancer vaccine HSPPC-96, is a personalized cancer vaccine developed by the American biopharmaceutical company Antigenics Inc. (now Agenus) that is evaluated in multiple clinical trials. It has been granted fast track and orphan drug designations from the US Food and Drug Administration for kidney cancer, metastatic melanoma, and glioma. In April 2009, the World Vaccine Congress named Oncophage as the best therapeutic vaccine.

AttributesValues
rdf:type
rdfs:label
  • Oncophage (en)
rdfs:comment
  • Oncophage (brand name Vitespen), also known as cancer vaccine heat shock protein peptide complex-96 and cancer vaccine HSPPC-96, is a personalized cancer vaccine developed by the American biopharmaceutical company Antigenics Inc. (now Agenus) that is evaluated in multiple clinical trials. It has been granted fast track and orphan drug designations from the US Food and Drug Administration for kidney cancer, metastatic melanoma, and glioma. In April 2009, the World Vaccine Congress named Oncophage as the best therapeutic vaccine. (en)
dct:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
has abstract
  • Oncophage (brand name Vitespen), also known as cancer vaccine heat shock protein peptide complex-96 and cancer vaccine HSPPC-96, is a personalized cancer vaccine developed by the American biopharmaceutical company Antigenics Inc. (now Agenus) that is evaluated in multiple clinical trials. It has been granted fast track and orphan drug designations from the US Food and Drug Administration for kidney cancer, metastatic melanoma, and glioma. The investigational agent is not yet approved in the US but was approved in Russia in April 2008 for patients who have earlier-stage kidney cancer. The European Medicines Agency is evaluating conditional approval for Oncophage. Oncophage is one of a group of new drugs called cancer vaccines that intend to train the body's immune system to fight the cancer. While chemotherapy is often accompanied by severe side effects, cancer vaccines tend to have only minimal ones (often only inflammations of the injection site). In April 2009, the World Vaccine Congress named Oncophage as the best therapeutic vaccine. However, after a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on 19 November 2009, Antigenics Inc. decided to withdraw their application for approval by the European Medicines Agency shortly after on 23 November 2009. (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git147 as of Sep 06 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3331 as of Sep 2 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 53 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software